Kronos Bio Inc KRON:NASDAQ

RT Quote | Last NASDAQ LS, VOL From CTA | USD
after hours iconAfter Hours: Last | 8:00 AM EDT
1.00quote price arrow up+0.02 (+1.85%)
Volume
2,325
Close
0.9818quote price arrow up+0.0004 (+0.0408%)
Volume
2,325
52 week range
0.73 - 2.29
Loading...
  • Open0.00
  • Day High0.00
  • Day Low0.00
  • Prev Close0.9818
  • 52 Week High2.29
  • 52 Week High Date07/13/23
  • 52 Week Low0.73
  • 52 Week Low Date11/14/23

Key Stats

  • Market Cap59.001M
  • Shares Out60.09M
  • 10 Day Average Volume0.00M
  • Dividend-
  • Dividend Yield-
  • Beta1.83
  • YTD % Change-21.49

KEY STATS

  • Open0.00
  • Day High0.00
  • Day Low0.00
  • Prev Close0.9818
  • 52 Week High2.29
  • 52 Week High Date07/13/23
  • 52 Week Low0.73
  • 52 Week Low Date11/14/23
  • Market Cap59.001M
  • Shares Out60.09M
  • 10 Day Average Volume0.00M
  • Dividend-
  • Dividend Yield-
  • Beta1.83
  • YTD % Change-21.49

RATIOS/PROFITABILITY

  • EPS (TTM)-2.00
  • P/E (TTM)-0.49
  • Fwd P/E (NTM)-0.66
  • EBITDA (TTM)-107.557M
  • ROE (TTM)-64.20%
  • Revenue (TTM)7.587M
  • Gross Margin (TTM)-
  • Net Margin (TTM)-1,534.11%
  • Debt To Equity (MRQ)-

EVENTS

  • Earnings Date08/06/2024(est)
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Kronos Bio Inc

 

Profile

MORE
Kronos Bio, Inc. is a biopharmaceutical company. The Company is focused on developing therapeutics that target the deregulated transcription that causes cancer and other serious diseases. It is developing KB-0742, its internally discovered oral cyclin dependent kinase 9 (CDK9) inhibitor, for the treatment of MYC-amplified and others transcriptionally addicted solid tumors. It has initiated the Phase 2 portion of its Phase 1/2 clinical trial for KB-0742. It is also developing...
Arie Belldegrun M.D.
Non-Executive Independent Chairman of the Board
Norbert Bischofberger Ph.D.
President, Chief Executive Officer, Director
Sandra Gardiner
Interim Chief Financial Officer
Address
1300 S. El Camino Real, Suite 400
San Mateo, CA
94402
United States

Top Peers

SYMBOLLASTCHG%CHG
KZR
Kezar Life Sciences Inc
0.768-0.0043-0.5568%
BLRX
BioLine RX Ltd
0.6419+0.025+4.0441%
LVTX
LAVA Therapeutics NV
2.76-0.07-2.47%
IKNA
Ikena Oncology Inc
1.40+0.06+4.87%
CUE
Cue Biopharma Inc
1.74+0.10+6.10%